Home Newsfeeds UBS Maintains Neutral on Carter’s, Lowers Price Target to $72

UBS Maintains Neutral on Carter’s, Lowers Price Target to $72

UBS analyst Jay Sole maintains Carter's (NYSE:CRI) with a Neutral and lowers the price target from $100 to $72.

byBenzinga Newsdesk

July 15, 2022

1 minute read

UBS analyst Jay Sole maintains Carter’s (NYSE:CRI) with a Neutral and lowers the price target from $100 to $72.

Rare Disease-Focused-Ultragenyx Pharmaceutical Stock Falls On Serious Adverse Events In Eaarly Genetic Disorder Study

By Vandana Singh

April 15, 10:40 AM

New data from Phase 1/2 study of GTX-102 for Angelman syndrome shows rapid and sustained improvement in patients, exceeding natural history data.

RARE

$3 Million Bet On Taysha Gene Therapies? Check Out These 3 Penny Stocks Insiders Are Buying

By Lisa Levin

November 3, 11:42 AM

The Dow Jones closed lower by more than 500 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

BDTX